NCT02856425View on ClinicalTrials.gov

Trial Of Pembrolizumab And Nintedanib

PHASE1RecruitingINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2028

Conditions
Patients With Any Advanced Solid Tumors
Interventions
DRUG

Nintedanib

Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

DRUG

Pembrolizumab

Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Trial Locations (5)

31059

RECRUITING

IUCT--O, Toulouse

33000

RECRUITING

Institut Bergonié, Bordeaux

69008

RECRUITING

Centre Léon Bérard, Lyon

75018

ACTIVE_NOT_RECRUITING

Hôpital Bichat, Paris

94805

RECRUITING

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER